1. Scrip
  2. >>Business
  3. >>Strategy

Can Denmark's ALK-Abello Crack The US Allergy Market?

 
• By John Davis

Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.

Dust mite
A house dust mite, a major cause of allergic rhinitis • Source: Shutterstock

Denmark's allergy therapies company, ALK-Abello AS, has become the latest European-headquartered firm to outline a corporate strategy that includes plans to crack the US allergists market, aiming to reduce the continued US reliance on "allergen extract" shots, and to boost the market for more recently developed allergy immunotherapy (AIT) treatments.

The focus on the US, with a planned DKK1bn ($159m) investment over three years, is a major cog in ALK-Abello's ambitions to transform from a niche company into a much broader-based allergy company, with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.